Floatz logo

Etx-19477

BRCA Mutation

858 Therapeutics, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the BRCA Mutation cohort.

Asset / SponsorPhaseRating
Olaparib
Okayama University
Phase 3B
Cyclophosphamide
Okayama University
Phase 2CCC
TAMOXIFEN
European Institute of Oncology
Phase 2CCC
Tranexamic Acid
Northwestern University
Phase 2CCC
Epirubicin
Okayama University
Phase 2CCC

View all 12 →

Same molecule, other indications

Etx-19477 is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
estrogen-receptor positive breast cancerDormant
CC
Indicative ·
47 / 100
View asset →
BRCA2-related cancer predispositionDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →